Compare Novo Nordisk A/S (NVO) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Oscar Health Inc — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while Oscar Health Inc trades at $31.74 (market cap $10.19B). The key difference: Novo Nordisk A/S is far larger — about 19.7× Oscar Health Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| NVO | OSCR | |
|---|---|---|
Market Cap | $200.69B | $10.19B |
Sector | Health | Health |
52-Week High | $63.98 | $33.01 |
52-Week Low | $35.29 | $10.85 |
Enterprise Value | $215.49B | $6.54B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Oscar Health (OSCR) trades at $33.01, up 2.36% today and approaching its 52-week high of $33.10. The stock shows strong technical momentum with bullish moving averages and has surged 109% year-to-date. Fundamentally, revenue grew from $11.7B in 2025 to $15.3B in 2026, with net income turning positive at $551M. Recent earnings beats and membership growth to 2.96 million support the bullish case, though valuation metrics like P/E of 25.39 and P/B of 4.97 suggest premium pricing.
Outlook remains positive with strong revenue growth and profitability improvements, but risks include high valuation multiples and dependence on sustained membership growth. Analyst consensus is mixed with 27% buy ratings and a $30.67 price target below current levels, indicating caution despite technical strength. Key catalysts include continued operational efficiency gains and AI integration, while medical cost management remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
